Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry
Pulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible electroporation. Unlike the traditional ablation energy sources, pulsed field ablation has demonstrated significant preferentiality to myocardi...
Uloženo v:
| Vydáno v: | Circulation (New York, N.Y.) Ročník 148; číslo 1; s. 35 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
04.07.2023
|
| Témata: | |
| ISSN: | 1524-4539, 1524-4539 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Pulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible electroporation. Unlike the traditional ablation energy sources, pulsed field ablation has demonstrated significant preferentiality to myocardial tissue ablation, and thus avoids certain thermally mediated complications. However, its safety and effectiveness remain unknown in usual clinical care.
MANIFEST-PF (Multi-National Survey on the Methods, Efficacy, and Safety on the Post-Approval Clinical Use of Pulsed Field Ablation) is a retrospective, multinational, patient-level registry wherein patients at each center were prospectively included in their respective center registries. The registry included all patients undergoing postapproval treatment with a multielectrode 5-spline pulsed field ablation catheter to treat atrial fibrillation (AF) between March 1, 2021, and May 30, 2022. The primary effectiveness outcome was freedom from clinical documented atrial arrhythmia (AF/atrial flutter/atrial tachycardia) of ≥30 seconds on the basis of electrocardiographic data after a 3-month blanking period (on or off antiarrhythmic drugs). Safety outcomes included the composite of acute (<7 days postprocedure) and latent (>7 days) major adverse events.
At 24 European centers (77 operators) pulsed field ablation was performed in 1568 patients with AF: age 64.5±11.5 years, female 35%, paroxysmal/persistent AF 65%/32%, CHA
DS
-VASc 2.2±1.6, median left ventricular ejection fraction 60%, and left atrial diameter 42 mm. Pulmonary vein isolation was achieved in 99.2% of patients. After a median (interquartile range) follow-up of 367 (289-421) days, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% (95% CI, 76.0%-80.0%); clinical effectiveness was more common in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%;
=0.001). Acute major adverse events occurred in 1.9% of patients.
In this large observational registry of the postapproval clinical use of pulsed field technology to treat AF, catheter ablation using pulsed field energy was clinically effective in 78% of patients with AF. |
|---|---|
| AbstractList | Pulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible electroporation. Unlike the traditional ablation energy sources, pulsed field ablation has demonstrated significant preferentiality to myocardial tissue ablation, and thus avoids certain thermally mediated complications. However, its safety and effectiveness remain unknown in usual clinical care.
MANIFEST-PF (Multi-National Survey on the Methods, Efficacy, and Safety on the Post-Approval Clinical Use of Pulsed Field Ablation) is a retrospective, multinational, patient-level registry wherein patients at each center were prospectively included in their respective center registries. The registry included all patients undergoing postapproval treatment with a multielectrode 5-spline pulsed field ablation catheter to treat atrial fibrillation (AF) between March 1, 2021, and May 30, 2022. The primary effectiveness outcome was freedom from clinical documented atrial arrhythmia (AF/atrial flutter/atrial tachycardia) of ≥30 seconds on the basis of electrocardiographic data after a 3-month blanking period (on or off antiarrhythmic drugs). Safety outcomes included the composite of acute (<7 days postprocedure) and latent (>7 days) major adverse events.
At 24 European centers (77 operators) pulsed field ablation was performed in 1568 patients with AF: age 64.5±11.5 years, female 35%, paroxysmal/persistent AF 65%/32%, CHA
DS
-VASc 2.2±1.6, median left ventricular ejection fraction 60%, and left atrial diameter 42 mm. Pulmonary vein isolation was achieved in 99.2% of patients. After a median (interquartile range) follow-up of 367 (289-421) days, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% (95% CI, 76.0%-80.0%); clinical effectiveness was more common in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%;
=0.001). Acute major adverse events occurred in 1.9% of patients.
In this large observational registry of the postapproval clinical use of pulsed field technology to treat AF, catheter ablation using pulsed field energy was clinically effective in 78% of patients with AF. Pulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible electroporation. Unlike the traditional ablation energy sources, pulsed field ablation has demonstrated significant preferentiality to myocardial tissue ablation, and thus avoids certain thermally mediated complications. However, its safety and effectiveness remain unknown in usual clinical care.BACKGROUNDPulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible electroporation. Unlike the traditional ablation energy sources, pulsed field ablation has demonstrated significant preferentiality to myocardial tissue ablation, and thus avoids certain thermally mediated complications. However, its safety and effectiveness remain unknown in usual clinical care.MANIFEST-PF (Multi-National Survey on the Methods, Efficacy, and Safety on the Post-Approval Clinical Use of Pulsed Field Ablation) is a retrospective, multinational, patient-level registry wherein patients at each center were prospectively included in their respective center registries. The registry included all patients undergoing postapproval treatment with a multielectrode 5-spline pulsed field ablation catheter to treat atrial fibrillation (AF) between March 1, 2021, and May 30, 2022. The primary effectiveness outcome was freedom from clinical documented atrial arrhythmia (AF/atrial flutter/atrial tachycardia) of ≥30 seconds on the basis of electrocardiographic data after a 3-month blanking period (on or off antiarrhythmic drugs). Safety outcomes included the composite of acute (<7 days postprocedure) and latent (>7 days) major adverse events.METHODSMANIFEST-PF (Multi-National Survey on the Methods, Efficacy, and Safety on the Post-Approval Clinical Use of Pulsed Field Ablation) is a retrospective, multinational, patient-level registry wherein patients at each center were prospectively included in their respective center registries. The registry included all patients undergoing postapproval treatment with a multielectrode 5-spline pulsed field ablation catheter to treat atrial fibrillation (AF) between March 1, 2021, and May 30, 2022. The primary effectiveness outcome was freedom from clinical documented atrial arrhythmia (AF/atrial flutter/atrial tachycardia) of ≥30 seconds on the basis of electrocardiographic data after a 3-month blanking period (on or off antiarrhythmic drugs). Safety outcomes included the composite of acute (<7 days postprocedure) and latent (>7 days) major adverse events.At 24 European centers (77 operators) pulsed field ablation was performed in 1568 patients with AF: age 64.5±11.5 years, female 35%, paroxysmal/persistent AF 65%/32%, CHA2DS2-VASc 2.2±1.6, median left ventricular ejection fraction 60%, and left atrial diameter 42 mm. Pulmonary vein isolation was achieved in 99.2% of patients. After a median (interquartile range) follow-up of 367 (289-421) days, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% (95% CI, 76.0%-80.0%); clinical effectiveness was more common in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%; P=0.001). Acute major adverse events occurred in 1.9% of patients.RESULTSAt 24 European centers (77 operators) pulsed field ablation was performed in 1568 patients with AF: age 64.5±11.5 years, female 35%, paroxysmal/persistent AF 65%/32%, CHA2DS2-VASc 2.2±1.6, median left ventricular ejection fraction 60%, and left atrial diameter 42 mm. Pulmonary vein isolation was achieved in 99.2% of patients. After a median (interquartile range) follow-up of 367 (289-421) days, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% (95% CI, 76.0%-80.0%); clinical effectiveness was more common in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%; P=0.001). Acute major adverse events occurred in 1.9% of patients.In this large observational registry of the postapproval clinical use of pulsed field technology to treat AF, catheter ablation using pulsed field energy was clinically effective in 78% of patients with AF.CONCLUSIONSIn this large observational registry of the postapproval clinical use of pulsed field technology to treat AF, catheter ablation using pulsed field energy was clinically effective in 78% of patients with AF. |
| Author | Metzner, Andreas Wakili, Reza Sommer, Philipp Deneke, Tom Gunawardene, Melanie Ouss, Alexandre Funasako, Moritoshi Rollin, Anne Chaumont, Corentin Scherr, Daniel Willems, Stephan Bohnen, Jan-Eric Boveda, Serge Reddy, Vivek Y Hansen, Jim Reichlin, Tobias Anic, Ante Fink, Thomas Roten, Laurent Derval, Nicolas Jais, Pierre van der Voort, Pepijn Manninger, Martin Sultan, Arian Kueffer, Thomas Maury, Philippe Anselme, Frédéric Turagam, Mohit K Rahe, Gilbert Vijgen, Johan Peichl, Petr Mulder, Bart A Nentwich, Karin Kautzner, Josef Neven, Kars Chun, Julian Neuzil, Petr Petru, Jan Adeliño, Raquel Blaauw, Yuri Jurisic, Zrinka Lehrmann, Heiko Arentz, Thomas Schmidt, Boris Koopman, Pieter Steven, Daniel Tilz, Roland Heeger, Christian-Hendrik Füting, Anna Lemoine, Marc D Ruwald, Martin |
| Author_xml | – sequence: 1 givenname: Mohit K orcidid: 0000-0001-8183-8443 surname: Turagam fullname: Turagam, Mohit K organization: Icahn School of Medicine at Mount Sinai, New York, NY (M.K.T., V.Y.R.) – sequence: 2 givenname: Petr orcidid: 0000-0003-4334-8165 surname: Neuzil fullname: Neuzil, Petr organization: Cardiology Department, Na Homolce Hospital, Homolka Hospital, Prague, Czechia (P.N., M.F., J.P., V.Y.R.) – sequence: 3 givenname: Boris orcidid: 0000-0001-5347-9906 surname: Schmidt fullname: Schmidt, Boris organization: MVZ CCB Frankfurt und Main-Taunus GbR, Frankfurt, Germany (B.S., J.C.) – sequence: 4 givenname: Tobias orcidid: 0000-0002-7197-8415 surname: Reichlin fullname: Reichlin, Tobias organization: Inselspital-Bern University Hospital, University of Bern, Switzerland (T.R., L.R., T.K.) – sequence: 5 givenname: Kars surname: Neven fullname: Neven, Kars organization: Department of Electrophysiology, Alfried Krupp Hospital, Essen, Germany (K. Neven, A.F.) – sequence: 6 givenname: Andreas surname: Metzner fullname: Metzner, Andreas organization: University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf, Germany (A.M., M.D.L.) – sequence: 7 givenname: Jim surname: Hansen fullname: Hansen, Jim organization: Copenhagen University Hospital, Denmark (J.H., M.R.) – sequence: 8 givenname: Yuri surname: Blaauw fullname: Blaauw, Yuri organization: Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands (Y.B., B.A.M.) – sequence: 9 givenname: Philippe orcidid: 0000-0002-4800-1841 surname: Maury fullname: Maury, Philippe organization: I2MC, INSERM UMR 1297, Toulouse, France (P.M.) – sequence: 10 givenname: Thomas surname: Arentz fullname: Arentz, Thomas organization: Department of Cardiology and Angiology, Medical Center and Faculty of Medicine- University of Freiburg, Germany (T.A., H.L.) – sequence: 11 givenname: Philipp surname: Sommer fullname: Sommer, Philipp organization: Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany (P.S., T.F.) – sequence: 12 givenname: Ante orcidid: 0000-0002-6864-3999 surname: Anic fullname: Anic, Ante organization: Department for Cardiovascular Diseases, University Hospital Center Split, Croatia (A.A., Z.J.) – sequence: 13 givenname: Frédéric orcidid: 0000-0002-2130-9790 surname: Anselme fullname: Anselme, Frédéric organization: Department of Cardiology, Rouen Hospital, France (F.A., C.C.) – sequence: 14 givenname: Serge orcidid: 0000-0002-8425-3544 surname: Boveda fullname: Boveda, Serge organization: Universitair Ziekenhuis VUB, Brussels, Belgium (S.B., R.A.) – sequence: 15 givenname: Tom orcidid: 0000-0003-1379-1684 surname: Deneke fullname: Deneke, Tom organization: Heart Center Bad Neustadt, Rhoen-Clinic Campus Bad Neustadt, Bad Neustadt an der Saale, Germany (T.D., K. Nentwich) – sequence: 16 givenname: Stephan surname: Willems fullname: Willems, Stephan organization: Asklepios Hospital St Georg, Hamburg, Germany (S.W., M.G.) – sequence: 17 givenname: Pepijn surname: van der Voort fullname: van der Voort, Pepijn organization: Department of Cardiology, Catharina Ziekenhuis Eindhoven, The Netherlands (P.v.d.V., A.O.) – sequence: 18 givenname: Roland orcidid: 0000-0002-0122-7130 surname: Tilz fullname: Tilz, Roland organization: German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany (R.T., C.-H.H.) – sequence: 19 givenname: Moritoshi surname: Funasako fullname: Funasako, Moritoshi organization: Neuron Medical, Brno, Czech Republic (M.F.) – sequence: 20 givenname: Daniel surname: Scherr fullname: Scherr, Daniel organization: Medical University of Graz, Austria (D. Scherr, M.M.) – sequence: 21 givenname: Reza orcidid: 0000-0002-6326-1537 surname: Wakili fullname: Wakili, Reza organization: Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Duisburg-Essen, Germany (R.W., J.-E.B.) – sequence: 22 givenname: Daniel orcidid: 0000-0001-6839-5895 surname: Steven fullname: Steven, Daniel organization: Heart Center University Hospital of Cologne, Department for Electrophysiology, Germany (D. Steven, A.S.) – sequence: 23 givenname: Josef orcidid: 0000-0002-1632-6182 surname: Kautzner fullname: Kautzner, Josef organization: IKEM-Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K., P.P.) – sequence: 24 givenname: Johan orcidid: 0000-0003-4928-4836 surname: Vijgen fullname: Vijgen, Johan organization: Department of Cardiology, Jessa Hospitals, Hasselt, Belgium (J.V., P.K.) – sequence: 25 givenname: Pierre orcidid: 0000-0002-4700-7811 surname: Jais fullname: Jais, Pierre organization: IHU LIRYC, CHU Bordeaux, University of Bordeaux, France (P.J., N.D.) – sequence: 26 givenname: Jan surname: Petru fullname: Petru, Jan organization: Cardiology Department, Na Homolce Hospital, Homolka Hospital, Prague, Czechia (P.N., M.F., J.P., V.Y.R.) – sequence: 27 givenname: Julian orcidid: 0000-0002-2355-6015 surname: Chun fullname: Chun, Julian organization: MVZ CCB Frankfurt und Main-Taunus GbR, Frankfurt, Germany (B.S., J.C.) – sequence: 28 givenname: Laurent orcidid: 0000-0002-0827-1329 surname: Roten fullname: Roten, Laurent organization: Inselspital-Bern University Hospital, University of Bern, Switzerland (T.R., L.R., T.K.) – sequence: 29 givenname: Anna orcidid: 0000-0003-2116-1690 surname: Füting fullname: Füting, Anna organization: Department of Electrophysiology, Alfried Krupp Hospital, Essen, Germany (K. Neven, A.F.) – sequence: 30 givenname: Marc D orcidid: 0000-0002-3799-7962 surname: Lemoine fullname: Lemoine, Marc D organization: University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf, Germany (A.M., M.D.L.) – sequence: 31 givenname: Martin surname: Ruwald fullname: Ruwald, Martin organization: Copenhagen University Hospital, Denmark (J.H., M.R.) – sequence: 32 givenname: Bart A orcidid: 0000-0002-4411-3918 surname: Mulder fullname: Mulder, Bart A organization: Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands (Y.B., B.A.M.) – sequence: 33 givenname: Anne surname: Rollin fullname: Rollin, Anne organization: Department of Cardiology, University Hospital Rangueil, Toulouse, France (P.M., A.R.) – sequence: 34 givenname: Heiko surname: Lehrmann fullname: Lehrmann, Heiko organization: Department of Cardiology and Angiology, Medical Center and Faculty of Medicine- University of Freiburg, Germany (T.A., H.L.) – sequence: 35 givenname: Thomas surname: Fink fullname: Fink, Thomas organization: Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany (P.S., T.F.) – sequence: 36 givenname: Zrinka orcidid: 0000-0001-7583-9036 surname: Jurisic fullname: Jurisic, Zrinka organization: Department for Cardiovascular Diseases, University Hospital Center Split, Croatia (A.A., Z.J.) – sequence: 37 givenname: Corentin orcidid: 0000-0001-7188-2686 surname: Chaumont fullname: Chaumont, Corentin organization: Department of Cardiology, Rouen Hospital, France (F.A., C.C.) – sequence: 38 givenname: Raquel orcidid: 0000-0002-8843-9370 surname: Adeliño fullname: Adeliño, Raquel organization: Universitair Ziekenhuis VUB, Brussels, Belgium (S.B., R.A.) – sequence: 39 givenname: Karin orcidid: 0000-0002-3590-5980 surname: Nentwich fullname: Nentwich, Karin organization: Heart Center Bad Neustadt, Rhoen-Clinic Campus Bad Neustadt, Bad Neustadt an der Saale, Germany (T.D., K. Nentwich) – sequence: 40 givenname: Melanie orcidid: 0000-0001-7561-7185 surname: Gunawardene fullname: Gunawardene, Melanie organization: Asklepios Hospital St Georg, Hamburg, Germany (S.W., M.G.) – sequence: 41 givenname: Alexandre surname: Ouss fullname: Ouss, Alexandre organization: Department of Cardiology, Catharina Ziekenhuis Eindhoven, The Netherlands (P.v.d.V., A.O.) – sequence: 42 givenname: Christian-Hendrik orcidid: 0000-0002-9014-8097 surname: Heeger fullname: Heeger, Christian-Hendrik organization: German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany (R.T., C.-H.H.) – sequence: 43 givenname: Martin orcidid: 0000-0002-0545-4373 surname: Manninger fullname: Manninger, Martin organization: Medical University of Graz, Austria (D. Scherr, M.M.) – sequence: 44 givenname: Jan-Eric surname: Bohnen fullname: Bohnen, Jan-Eric organization: Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Duisburg-Essen, Germany (R.W., J.-E.B.) – sequence: 45 givenname: Arian surname: Sultan fullname: Sultan, Arian organization: Heart Center University Hospital of Cologne, Department for Electrophysiology, Germany (D. Steven, A.S.) – sequence: 46 givenname: Petr orcidid: 0000-0002-5625-0071 surname: Peichl fullname: Peichl, Petr organization: IKEM-Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K., P.P.) – sequence: 47 givenname: Pieter orcidid: 0000-0002-6373-180X surname: Koopman fullname: Koopman, Pieter organization: Department of Cardiology, Jessa Hospitals, Hasselt, Belgium (J.V., P.K.) – sequence: 48 givenname: Nicolas orcidid: 0000-0002-6189-1308 surname: Derval fullname: Derval, Nicolas organization: IHU LIRYC, CHU Bordeaux, University of Bordeaux, France (P.J., N.D.) – sequence: 49 givenname: Thomas orcidid: 0000-0003-3553-4945 surname: Kueffer fullname: Kueffer, Thomas organization: Inselspital-Bern University Hospital, University of Bern, Switzerland (T.R., L.R., T.K.) – sequence: 50 givenname: Gilbert surname: Rahe fullname: Rahe, Gilbert organization: Department of Pulmonology, Gastroenterology and Internal Medicine, Alfried Krupp Hospital, Essen, Germany (G.R.) – sequence: 51 givenname: Vivek Y orcidid: 0000-0002-5638-4993 surname: Reddy fullname: Reddy, Vivek Y organization: Cardiology Department, Na Homolce Hospital, Homolka Hospital, Prague, Czechia (P.N., M.F., J.P., V.Y.R.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37199171$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUEtLAzEYDFJRW_0LEm9etuZL9hVvS-naQm2L1oOnkt180ZV9aJIVevKvW7GCpxmYYWaYIRm0XYuEXAEbA8RwM5k_TJ4W2Wa-WmazbAxcjFkcykgekTOIeBiEkZCDf_yUDJ17Y4zFIolOyKlIQEpI4Ix8PSqDfkdVq-nUGCx99YktOkc7Q9d97VDTvMJa06yola-6lvqObiwqTzNvK1Xv5cJW9a94S1ctBs-oLF31vuwadDS3XUP9K9L7bDnPp4-bYJ3TB3ypnLe7c3Js1L7l4oAj8pRPN5NZsFjdzSfZIijDMImDSCjBCwago1LqRDIhUlClLArQwI2JgccoyliCiUwYMpUChlCiTgvJkWk-Ite_ue-2--jR-W1TuRL3s1vserfl6c9ZqYz43np5sPZFg3r7bqtG2d327zT-DdfHclc |
| CitedBy_id | crossref_primary_10_1007_s10840_024_01876_x crossref_primary_10_1016_j_hrthm_2024_05_048 crossref_primary_10_1016_j_hrthm_2024_09_061 crossref_primary_10_15420_aer_2023_16 crossref_primary_10_1016_j_hrthm_2025_07_054 crossref_primary_10_1111_jce_16402 crossref_primary_10_1016_j_jacep_2024_05_002 crossref_primary_10_3390_jcm13030679 crossref_primary_10_1093_europace_euae180 crossref_primary_10_1111_jce_16761 crossref_primary_10_1007_s00399_024_01007_z crossref_primary_10_1007_s10840_024_01961_1 crossref_primary_10_1016_j_hrthm_2024_11_031 crossref_primary_10_1016_j_hrcr_2024_04_013 crossref_primary_10_1161_CIRCEP_123_012255 crossref_primary_10_1016_j_ccep_2025_02_005 crossref_primary_10_1016_j_hrthm_2025_08_010 crossref_primary_10_1016_j_ccep_2025_02_004 crossref_primary_10_1016_j_ijcha_2025_101684 crossref_primary_10_1016_j_hrcr_2025_08_023 crossref_primary_10_1161_CIRCEP_125_013977 crossref_primary_10_1016_j_jaccas_2025_104811 crossref_primary_10_1038_s41591_024_03114_3 crossref_primary_10_1016_j_ccep_2025_02_006 crossref_primary_10_1016_j_tcm_2025_07_008 crossref_primary_10_3390_jcdd11060175 crossref_primary_10_1007_s10840_025_02124_6 crossref_primary_10_1016_j_hrthm_2024_05_042 crossref_primary_10_1016_j_hrthm_2025_01_021 crossref_primary_10_1016_j_hrthm_2025_01_022 crossref_primary_10_1016_j_jacep_2025_02_037 crossref_primary_10_3390_bioengineering12040329 crossref_primary_10_1016_j_hrcr_2025_04_020 crossref_primary_10_3390_jcm14062071 crossref_primary_10_1093_postmj_qgaf049 crossref_primary_10_1016_j_hrthm_2024_11_023 crossref_primary_10_1093_europace_euae194 crossref_primary_10_3390_jcdd11110356 crossref_primary_10_1016_j_hrcr_2024_04_004 crossref_primary_10_3389_fcvm_2024_1426920 crossref_primary_10_1016_j_hrthm_2025_06_006 crossref_primary_10_1093_ehjopen_oeae014 crossref_primary_10_1111_pace_15141 crossref_primary_10_3389_fcvm_2024_1266195 crossref_primary_10_1056_NEJMc2313783 crossref_primary_10_1016_j_hrthm_2024_05_032 crossref_primary_10_1016_j_hroo_2025_08_027 crossref_primary_10_1007_s10840_024_01735_9 crossref_primary_10_1016_j_hroo_2025_04_005 crossref_primary_10_1016_j_hrthm_2024_10_070 crossref_primary_10_1080_17434440_2025_2463340 crossref_primary_10_1161_CIRCULATIONAHA_124_070333 crossref_primary_10_1007_s10840_023_01624_7 crossref_primary_10_1007_s10840_025_02130_8 crossref_primary_10_1002_joa3_13174 crossref_primary_10_1016_j_hrthm_2024_09_041 crossref_primary_10_1016_j_jacep_2023_12_015 crossref_primary_10_1007_s00399_025_01071_z crossref_primary_10_1016_j_hrthm_2025_06_033 crossref_primary_10_1161_CIRCEP_123_012278 crossref_primary_10_1016_j_hrthm_2024_02_010 crossref_primary_10_1093_europace_euaf012 crossref_primary_10_1161_CIRCEP_124_013088 crossref_primary_10_1161_CIRCEP_123_012667 crossref_primary_10_3390_jcm13226961 crossref_primary_10_1016_j_hrcr_2025_08_003 crossref_primary_10_1093_europace_euae202 crossref_primary_10_1093_europace_euae207 crossref_primary_10_1111_pace_15154 crossref_primary_10_1007_s10840_023_01696_5 crossref_primary_10_1016_j_repc_2025_02_003 crossref_primary_10_1111_jce_70078 crossref_primary_10_1038_s41598_025_88447_w crossref_primary_10_1097_HCO_0000000000001094 crossref_primary_10_3389_fcvm_2025_1631253 crossref_primary_10_1093_europace_euae174 crossref_primary_10_1007_s00399_024_01047_5 crossref_primary_10_1016_j_repc_2024_09_006 crossref_primary_10_1016_j_hrthm_2025_01_015 crossref_primary_10_1016_j_jacasi_2024_09_014 crossref_primary_10_1016_j_jacc_2025_03_515 crossref_primary_10_1016_j_ccep_2025_02_014 crossref_primary_10_1016_j_ijcard_2025_133135 crossref_primary_10_1161_CIRCEP_124_013645 crossref_primary_10_1002_hsr2_70439 crossref_primary_10_1111_pace_15166 crossref_primary_10_3390_jcm13237040 crossref_primary_10_1186_s12951_024_02540_2 crossref_primary_10_1016_j_jacep_2025_02_006 crossref_primary_10_1016_j_hrthm_2025_02_033 crossref_primary_10_3390_jcm13175031 crossref_primary_10_1093_icvts_ivaf184 crossref_primary_10_1111_jce_16326 crossref_primary_10_1093_europace_euaf193 crossref_primary_10_1007_s10840_024_01771_5 crossref_primary_10_1111_jce_16728 crossref_primary_10_1007_s10840_024_01835_6 crossref_primary_10_1007_s10840_025_02021_y crossref_primary_10_1016_j_hrthm_2024_04_046 crossref_primary_10_1016_j_jacep_2025_03_038 crossref_primary_10_1016_j_hroo_2025_05_017 crossref_primary_10_1016_j_hrthm_2024_04_045 crossref_primary_10_1016_j_hroo_2024_05_008 crossref_primary_10_36660_abc_20240845i crossref_primary_10_1080_17434440_2024_2447809 crossref_primary_10_1161_JAHA_124_037959 crossref_primary_10_1007_s10840_023_01655_0 crossref_primary_10_1016_j_hrcr_2025_05_017 crossref_primary_10_1136_bcr_2024_263763 crossref_primary_10_1002_joa3_13118 crossref_primary_10_1007_s10840_023_01651_4 crossref_primary_10_1111_pace_15177 crossref_primary_10_1007_s10840_023_01708_4 crossref_primary_10_1016_j_hrthm_2025_09_024 crossref_primary_10_1016_j_jacep_2025_04_008 crossref_primary_10_1016_j_hrcr_2025_05_015 crossref_primary_10_1016_j_jacc_2024_05_011 crossref_primary_10_1016_j_jacep_2023_06_019 crossref_primary_10_1111_jce_16797 crossref_primary_10_3389_fcvm_2025_1679578 crossref_primary_10_1016_j_hrthm_2024_03_009 crossref_primary_10_1002_joa3_70011 crossref_primary_10_1002_joa3_13180 crossref_primary_10_1016_j_jacep_2024_01_017 crossref_primary_10_1080_17434440_2025_2475239 crossref_primary_10_1007_s10840_025_02036_5 crossref_primary_10_1016_j_hlc_2025_04_088 crossref_primary_10_1007_s00399_024_01035_9 crossref_primary_10_1016_j_hrthm_2025_08_045 crossref_primary_10_1007_s11936_024_01051_5 crossref_primary_10_1016_j_jacep_2024_102330 crossref_primary_10_1111_pace_15221 crossref_primary_10_1111_pace_15101 crossref_primary_10_1136_openhrt_2024_003094 crossref_primary_10_3389_fcvm_2025_1627579 crossref_primary_10_3390_jcdd12010010 crossref_primary_10_1016_j_hrthm_2024_07_024 crossref_primary_10_1016_j_hrthm_2024_09_015 crossref_primary_10_1016_j_jacep_2025_04_017 crossref_primary_10_1136_bmjopen_2023_079881 crossref_primary_10_1111_jce_16742 crossref_primary_10_1007_s12325_024_02877_y crossref_primary_10_1056_NEJMoa2307291 crossref_primary_10_1016_j_hroo_2025_08_042 crossref_primary_10_1016_j_hrthm_2024_03_017 crossref_primary_10_1111_pace_14947 crossref_primary_10_1016_j_hrthm_2025_02_017 crossref_primary_10_1097_HCO_0000000000001183 crossref_primary_10_1007_s10840_024_01853_4 crossref_primary_10_1111_jce_16101 crossref_primary_10_1111_jce_16507 crossref_primary_10_1016_j_hrthm_2024_04_102 crossref_primary_10_3390_jcm14061891 crossref_primary_10_1016_j_plrev_2023_08_010 crossref_primary_10_1186_s40001_025_02286_z crossref_primary_10_1007_s10840_024_01748_4 crossref_primary_10_1038_s41569_024_01053_7 crossref_primary_10_1016_j_hroo_2025_07_002 crossref_primary_10_1016_j_jacep_2025_06_036 crossref_primary_10_3390_medicina60050817 crossref_primary_10_1097_HCO_0000000000001181 crossref_primary_10_1016_j_hrthm_2025_07_022 crossref_primary_10_3390_jcm13102980 crossref_primary_10_1111_jce_16056 crossref_primary_10_1111_jce_16573 crossref_primary_10_1093_europace_euaf182 crossref_primary_10_3390_biomedicines12102232 crossref_primary_10_1016_j_hrthm_2024_10_045 crossref_primary_10_1016_j_cpcardiol_2024_102514 crossref_primary_10_3390_jcm14145147 crossref_primary_10_1016_j_hlc_2023_10_012 crossref_primary_10_1016_j_jacep_2025_01_017 crossref_primary_10_1093_europace_euaf185 crossref_primary_10_1097_HCO_0000000000001217 crossref_primary_10_3390_jcm13113113 crossref_primary_10_1002_joa3_13082 crossref_primary_10_1016_j_hrcr_2024_10_018 crossref_primary_10_1007_s10840_024_01970_0 crossref_primary_10_1093_eurheartjsupp_suae103 crossref_primary_10_1016_j_hrthm_2024_06_058 crossref_primary_10_36660_abc_20240845 crossref_primary_10_1016_j_hrthm_2024_08_040 crossref_primary_10_1016_j_hrthm_2025_03_161 crossref_primary_10_1161_CIRCULATIONAHA_125_074485 crossref_primary_10_3390_jcm13175191 crossref_primary_10_1016_j_jacc_2024_05_001 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1161/CIRCULATIONAHA.123.064959 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1524-4539 |
| ExternalDocumentID | 37199171 |
| Genre | Journal Article |
| GroupedDBID | --- .-D .3C .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAAV AAAXR AAFWJ AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAWTL AAXQO ABASU ABBUW ABDIG ABJNI ABOCM ABPMR ABPXF ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACLDA ACOAL ACRKK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADCYY ADGGA ADHPY AE3 AE6 AEBDS AENEX AFBFQ AFCHL AFDTB AFEXH AFMBP AFNMH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIK DIWNM DU5 E3Z EBS ECM EEVPB EIF ERAAH EX3 F2K F2L F2M F2N F5P FCALG GNXGY GQDEL GX1 H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 K-A K-F K8S KD2 KMI KQ8 L-C L7B N9A NPM N~7 N~B O9- OAG OAH OBH OCB ODMTH OGEVE OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WOQ WOW X3V X3W XXN XYM YFH YOC YSK YYM YZZ ZFV ZY1 ~H1 7X8 ADKSD ADSXY |
| ID | FETCH-LOGICAL-c4476-53a32b011d5c9d7903381ac9bb1d12ff6126e3c691f5f440a81e41ced8b92e0d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 215 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00003017-202307040-00006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1524-4539 |
| IngestDate | Wed Oct 01 13:42:27 EDT 2025 Mon Jul 21 06:00:53 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | atrial fibrillation catheter ablation irreversible electroporation therapy treatment outcome |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4476-53a32b011d5c9d7903381ac9bb1d12ff6126e3c691f5f440a81e41ced8b92e0d2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-0122-7130 0000-0003-2116-1690 0000-0002-2130-9790 0000-0002-6373-180X 0000-0001-7583-9036 0000-0001-7561-7185 0000-0002-7197-8415 0000-0003-1379-1684 0000-0002-4700-7811 0000-0003-3553-4945 0000-0002-1632-6182 0000-0002-6189-1308 0000-0001-6839-5895 0000-0002-6864-3999 0000-0002-0827-1329 0000-0002-8843-9370 0000-0002-5625-0071 0000-0001-8183-8443 0000-0002-3799-7962 0000-0002-9014-8097 0000-0002-8425-3544 0000-0002-3590-5980 0000-0001-7188-2686 0000-0002-6326-1537 0000-0002-4411-3918 0000-0002-2355-6015 0000-0001-5347-9906 0000-0002-0545-4373 0000-0002-5638-4993 0000-0003-4334-8165 0000-0003-4928-4836 0000-0002-4800-1841 |
| OpenAccessLink | https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.123.064959 |
| PMID | 37199171 |
| PQID | 2815248952 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2815248952 pubmed_primary_37199171 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-Jul-04 20230704 |
| PublicationDateYYYYMMDD | 2023-07-04 |
| PublicationDate_xml | – month: 07 year: 2023 text: 2023-Jul-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Circulation (New York, N.Y.) |
| PublicationTitleAlternate | Circulation |
| PublicationYear | 2023 |
| SSID | ssj0006375 |
| Score | 2.7206893 |
| Snippet | Pulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 35 |
| SubjectTerms | Aged Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Atrial Fibrillation - surgery Atrial Flutter - etiology Catheter Ablation - adverse effects Catheter Ablation - methods Female Humans Middle Aged Pulmonary Veins Recurrence Registries Retrospective Studies Stroke Volume Treatment Outcome Ventricular Function, Left |
| Title | Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37199171 https://www.proquest.com/docview/2815248952 |
| Volume | 148 |
| WOSCitedRecordID | wos00003017-202307040-00006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBZtUkIvaZv0kaYtEyi9qbEsWY9eglliEuhulmQD29MiW1LpIXa6j0JO_esdyQ65lUIvvgiBLY--b17MR8jHgHYjLZdUWuWpQMJFHLSKIvlxpXSRW58lsQk1mej53EyHhNtqaKu8x8QE1K5rYo78ONfINEKbIj-5_UmjalSsrg4SGo_JNkdXJlq1mj9MC5c8DdqNG6kouNkhRwkkJDsenV-Orr_2A2fPYkaQf0ZyNsVfPM3EONWz_33X52R38DWh7I3jBXnk2z2yX7YYZ9_cwSdI3Z8prb5HdsZDkX2f_L6ywa_vwLYO-uHGAyJCF2C6QS51UMXGNyjrvpMO1h3MovcJZVIBweV6GeWM4uIXuGg9_YY3Ci42a_wAv4Jq2d0Aup4wLifn1enVjE4ruPTfk_TcS3Jdnc5GZ3TQaaCNEErSglue1wgUrmiMUybDsJfZxtQ1cywPAZ0o6XkjDQtFECKzmnnBGu90bXKfufwV2Wq71r8h4HITbIGhMtNaBBe0CoxrqfJMee9VOCBH9ye-wHsQixu29d1mtXg48wPyuv9ti9t-YMeCq9jgpdjbf9h9SJ5GRfnUkSveke2AKODfkyfNr_WP1fJDMjB8TqbjPy_T2BU |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+Effectiveness+of+Pulsed+Field+Ablation+to+Treat+Atrial+Fibrillation%3A+One-Year+Outcomes+From+the+MANIFEST-PF+Registry&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Turagam%2C+Mohit+K&rft.au=Neuzil%2C+Petr&rft.au=Schmidt%2C+Boris&rft.au=Reichlin%2C+Tobias&rft.date=2023-07-04&rft.issn=1524-4539&rft.eissn=1524-4539&rft.volume=148&rft.issue=1&rft.spage=35&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.123.064959&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1524-4539&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1524-4539&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1524-4539&client=summon |